Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H30NO4S2 |
Molecular Weight | 484.651 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 2 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
OC(C(=O)O[C@H]1C[N+]3(CCCOC2=CC=CC=C2)CCC1CC3)(C4=CC=CS4)C5=CC=CS5
InChI
InChIKey=ASMXXROZKSBQIH-VITNCHFBSA-N
InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1
Molecular Formula | C26H29NO4S2 |
Molecular Weight | 483.643 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including: | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002706/WC500132734.pdf | http://www.ncbi.nlm.nih.gov/pubmed/?term=24587893 | https://www.ncbi.nlm.nih.gov/pubmed/19710368
Curator's Comment: description was created based on several sources, including: | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002706/WC500132734.pdf | http://www.ncbi.nlm.nih.gov/pubmed/?term=24587893 | https://www.ncbi.nlm.nih.gov/pubmed/19710368
Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
CNS Activity
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002706/WC500132734.pdf
Curator's Comment: The polar nature of aclidinium bromide makes it unlikely to cross the blood brain barrier
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.14 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | TUDORZA PRESSAIR Approved UseIndicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema Launch Date2012 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
240.5 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22366196/ |
400 μg 2 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ACLIDINIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
194.2 pg/mL DRUG LABEL https://pubmed.ncbi.nlm.nih.gov/22366196/ |
400 μg single, oral dose: 400 μg route of administration: Oral experiment type: SINGLE co-administered: |
ACLIDINIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
468.4 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22366196/ |
400 μg 2 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ACLIDINIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
386.7 pg × h/mL DRUG LABEL https://pubmed.ncbi.nlm.nih.gov/22366196/ |
400 μg single, oral dose: 400 μg route of administration: Oral experiment type: SINGLE co-administered: |
ACLIDINIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22366196/ |
400 μg 2 times / day steady-state, oral dose: 400 μg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ACLIDINIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.9 h DRUG LABEL https://pubmed.ncbi.nlm.nih.gov/22366196/ |
400 μg single, oral dose: 400 μg route of administration: Oral experiment type: SINGLE co-administered: |
ACLIDINIUM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 ug single, intravenous Dose: 400 ug Route: intravenous Route: single Dose: 400 ug Sources: |
healthy, 30 years (range: 24-43 years) Health Status: healthy Age Group: 30 years (range: 24-43 years) Sex: M Sources: |
|
800 ug 2 times / day steady, respiratory Highest studied dose Dose: 800 ug, 2 times / day Route: respiratory Route: steady Dose: 800 ug, 2 times / day Sources: |
healthy, 39.3 years (range: 18-45 years) Health Status: healthy Age Group: 39.3 years (range: 18-45 years) Sex: M+F Sources: |
Other AEs: Muscle spasm, Dysgeusia... Other AEs: Muscle spasm (12.5%) Sources: Dysgeusia (12.5%) Somnolence (12.5%) |
6000 ug single, respiratory Highest studied dose Dose: 6000 ug Route: respiratory Route: single Dose: 6000 ug Sources: |
healthy |
|
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Non-cardiac chest pain, Headache... AEs leading to discontinuation/dose reduction: Non-cardiac chest pain (0.3%) Sources: Headache (0.2%) Dyspnea (0.2%) COPD (2%) Pruritus (0.2%) Syncope (0.2%) |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Fatigue, Non-cardiac chest pain... AEs leading to discontinuation/dose reduction: Fatigue (0.4%) Sources: Non-cardiac chest pain (0.2%) Dizziness (0.4%) Dyspnea (0.2%) COPD (2.9%) Pruritus (0.2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dysgeusia | 12.5% | 800 ug 2 times / day steady, respiratory Highest studied dose Dose: 800 ug, 2 times / day Route: respiratory Route: steady Dose: 800 ug, 2 times / day Sources: |
healthy, 39.3 years (range: 18-45 years) Health Status: healthy Age Group: 39.3 years (range: 18-45 years) Sex: M+F Sources: |
Muscle spasm | 12.5% | 800 ug 2 times / day steady, respiratory Highest studied dose Dose: 800 ug, 2 times / day Route: respiratory Route: steady Dose: 800 ug, 2 times / day Sources: |
healthy, 39.3 years (range: 18-45 years) Health Status: healthy Age Group: 39.3 years (range: 18-45 years) Sex: M+F Sources: |
Somnolence | 12.5% | 800 ug 2 times / day steady, respiratory Highest studied dose Dose: 800 ug, 2 times / day Route: respiratory Route: steady Dose: 800 ug, 2 times / day Sources: |
healthy, 39.3 years (range: 18-45 years) Health Status: healthy Age Group: 39.3 years (range: 18-45 years) Sex: M+F Sources: |
Dyspnea | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Headache | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Pruritus | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Syncope | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Non-cardiac chest pain | 0.3% Disc. AE |
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
COPD | 2% Disc. AE |
200 ug 2 times / day steady, respiratory Recommended Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dyspnea | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Non-cardiac chest pain | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Pruritus | 0.2% Disc. AE |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dizziness | 0.4% Disc. AE |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Fatigue | 0.4% Disc. AE |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
COPD | 2.9% Disc. AE |
200 ug 2 times / day steady, respiratory Dose: 200 ug, 2 times / day Route: respiratory Route: steady Dose: 200 ug, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
Page: 9.0 |
unlikely |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000PharmR.pdf#page=147 Page: 147.0 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:37 GMT 2025
by
admin
on
Mon Mar 31 18:01:37 GMT 2025
|
Record UNII |
K17VY42F6C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
BRIMICA GENUAIR ( AUTHORIZED: PLUMONARY DISEASE, CRONIC OBSTRUCTIVE)
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
||
|
WHO-ATC |
R03BB05
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
||
|
NDF-RT |
N0000175574
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
||
|
WHO-ATC |
R03AL05
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
K17VY42F6C
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
100000135703
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
727649-81-2
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
11434515
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
DTXSID00223070
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
DB08897
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
Aclidinium
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
7449
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
SUB71686
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
Aclidinium
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
1303098
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | RxNorm | ||
|
C79894
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY | |||
|
K17VY42F6C
Created by
admin on Mon Mar 31 18:01:37 GMT 2025 , Edited by admin on Mon Mar 31 18:01:37 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET->ANTAGONIST |
Ki
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET -> INHIBITOR |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
in healthy subjects
MAJOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL; PLASMA
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||